Secreted phospholipase A~2~ (sPLA~2~) are enzymes that hydrolyze the acyl ester at the sn-2 position of sn-3 glycerophospholipids,^[@ref1]^ a process characterized by complex interfacial kinetics of substrate--enzyme binding and catalysis.^[@ref2]^ Eleven sPLA~2~ enzymes (group Ib-XIIb) have so far been identified in mammals,^[@ref3]−[@ref5]^ several of which have been detected in human atherosclerotic lesions.^[@ref6]^ Among these, group IIa, V, and X sPLA~2~ isoforms are present in human carotid atherosclerotic lesions and have been associated with disease progression. They have been implicated in several proatherogenic actions in the arterial wall.^[@ref7]−[@ref9]^ Due to their hydrolytic action on lipoprotein phospholipids, sPLA~2~s promote lipid accumulation, induce significant lipoprotein remodeling, macrophage activation, and foam cell formation.^[@ref10],[@ref11]^ Furthermore, as the rate-limiting step in eicosanoid production, sPLA~2~-mediated release of arachidonic acid from the *sn*-2 position of phospholipids renders them highly pro-inflammatory enzymes.^[@ref10],[@ref11]^ In addition, epidemiological data has shown that increased levels of sPLA~2~ protein and sPLA~2~ activity are independently associated with risk of cardiovascular events and prevalence of atherosclerosis.^[@ref11]^ Owing to the pivotal role of sPLA~2~s in regulating lipoprotein function and inflammatory mechanisms, two crucial components of atherogenesis, sPLA~2~ inhibitors^[@ref12]^ could be useful for the treatment of atherosclerosis. Interestingly, the archetypal sPLA~2~ inhibitor varespladib methyl ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) was evaluated in short duration clinical trials for the treatment of rheumatoid arthritis and acute coronary syndrome with negative results.^[@ref13],[@ref14]^

![sPLA~2~ inhibitor varespladib methyl, its active metabolite varespladib, and initial fragment hit **1**.](ml-2016-001885_0001){#fig1}

We thus set out to identify novel sPLA~2~ inhibitors that could be used in longer term coronary artery disease-based clinical studies to more properly assess the relevance of their lipoprotein-modifying effects^[@ref15]−[@ref17]^ on cardiovascular disease, alongside their anti-inflammatory properties.

Given the competitive landscape, medicinal chemistry precedents and available structural information for sPLA~2~ enzymes, we opted for a structure-based fragment approach to maximize the chances of novelty and developability.^[@ref18]^ Analysis of potency data in combination with the available ligand-bound sPLA~2~ crystal structures^[@ref19]^ indicated that primary amides are extremely effective sPLA~2~ warheads, as they establish three hydrogen bonds with sPLA~2~ and one coordination bond with the catalytic calcium ion. We assembled a selection of primary aromatic carboxamide-containing fragments (heavy atom count ≥10 and ≤18) by mining in house biochemical and biophysical assay data against the sPLA~2~-IIa and sPLA~2~-X isoforms. The selection was based on activity against sPLA~2~-IIa, which is the most widely expressed isoform in humans,^[@ref20]^ but also on inspection of crystal structures and chemical evolution potential.

The triaging process identified compound **1** (LE: 0.39) originating from a legacy fragment/HTS campaign as the most promising fragment lead. As the translatability to a clinical setting was of special importance, we also triaged the activities for sPLA~2~ activity inhibition in human plasma (the mode-of-action biomarker to be used in clinical trials), as measured using a previously established protocol.^[@ref21]^

Compound **1** inhibited sPLA~2~-IIa (IC~50~: 24 μM) and human plasma sPLA~2~ activity (IC~u,50~: 0.9 μM) in a concentration dependent manner ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Going forward, as plasma sPLA~2~ activity is the result of various sPLA~2~ isoforms and we were interested in identifying a broad spectrum sPLA~2~ inhibitor, we also monitored inhibition of sPLA~2~-V and sPLA~2~-X, given their potential role in lipoprotein modulation.^[@ref16]^ Lastly, to avoid the need for a prodrug strategy (e.g., varespladib methyl) we carefully evaluated compound lipophilicity against passive permeability, solubility, and metabolic stability, prior to verifying the pharmacokinetic (PK) and pharmacodynamic (PD) profile *in vivo*.

###### Initial Profile for the Fragment Hit **1**

  entry         sPLA~2~-IIa IC~50~ (μM)   plasma IC~u,50~ (μM)[a](#t1fn1){ref-type="table-fn"}   *F*~u~ (%)   LE/LLE[b](#t1fn2){ref-type="table-fn"}
  ------------- ------------------------- ------------------------------------------------------ ------------ ----------------------------------------
  varespladib   0.028                     0.008                                                  12.5         0.37/7.2
  **1**         24                        0.9                                                    1.8          0.39/2.2

Calculated as plasma sPLA~2~ IC~50~ (μM) × compound's unbound fraction in human plasma (*F*~u~)/100. *F*~u~ = 100 -- human protein binding (%).

Ligand efficiency, LE (kcal/mol/HAC), calculated as −*RT* ln(sPLA~2~-IIa IC~50~)/heavy atom count. Ligand lipophilicity efficiency (LLE) calculated as pIC~50~ (sPLA~2~-IIa) -- logD.

The crystal structure of **1** bound to sPLA~2~-X confirmed the binding mode of the primary amide, with hydrogen-bonding to sPLA~2~-X's G28, H46, and D47 (corresponding to sPLA2-IIa G29, H47, and D48) and coordination to the calcium ion was observed, as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. Additionally, the 4-benzyl substituent was located in a lipophilic pocket consisting of residues I2, L5, A6, V9, P17, I18, and M21 (corresponding to L2, F5, H6, I9, A17, A18, and G22 in sPLA~2~-IIa, [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). While the two sPLA~2~ isoforms are identical in the amide coordinating residues, the lipophilic pocket that accommodates the benzyl group is slightly smaller in sPLA2-IIa. However, superposition of the sPLA~2~-IIa and sPLA~2~-X crystal structures suggested that the benzyl group of **1** could fit in the slightly smaller sPLA~2~-IIa pocket.

![Superposition of the crystal structure of **1** bound to sPLA~2~-X (cyan) and a crystal structure of sPLA~2~-IIa (gray). Residues that differ between the two isoforms are labeled in cyan and gray, respectively. The calcium ion is depicted as a purple sphere and hydrogen bonds are displayed as dashed lines.](ml-2016-001885_0002){#fig2}

We therefore devised a chemical exploration strategy starting from the binding mode of **1**. Here, special effort was placed upon establishing a second coordination bond to the catalytic calcium ion. The reasoning was 2-fold: (a) to increase affinity and functional inhibition of the enzyme as a result of a bidentate calcium chelate and additional van der Waals contact with the enzyme, and (b) to allow a more balanced lipophilicity profile of the final compounds as the additional calcium interacting moiety was anticipated to be a carboxylic acid. The *ortho* position of the benzamide ring was identified as a favorable substitution vector to deploy such a strategy. Based on iterative molecular modeling and careful consideration of theoretical affinity gain and ligand efficiency prediction, we synthesized compounds **2**--**6**, according to [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} (for compound **4** refer to [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Key steps involved the formation of the boronic acid by *ortho* lithiation^[@ref22]^ of the 4-benzylbenzonitrile (step b) followed by a Suzuki--Miyaura coupling and a controlled hydrolysis (step d) to generate both the amide and carboxylic acid functions ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![General Synthesis of Compounds **2**, **3**, **5**, and **6**\
Conditions: (a) benzylzinc bromide, Pd(Ph~3~)~4~, THF, 60 °C. (b) 1. *n*BuLi, tetramethylpiperidine; 2. B(OiPr)~3~, THF −78 °C. (c) Compound **2**, **3**, **5**: 3-bromophenyl carboxylic acid **A,** PdCl~2~(dppf), Cs~2~CO~3~, DMF, 60--90 °C. Compound **6**: Pd(P(Ph~3~)~4~, Cs2CO3, DMF 90. (d) Compound **2**, **3**, **5**: *n*-propanol/H~2~O (10:1), KOH (10 equiv), 80--100 °C, or THF, H~2~SO~4~. Compound **6**: KOH (10 equiv), MeOH/H~2~O, microwave 130 °C, 20 min.](ml-2016-001885_0005){#sch1}

![General Synthesis of sPLA~2~ Inhibitors **4** and **7**--**9**\
Conditions: (a) appropriate malonate, Cs~2~CO~3~, DMF, 70 °C, 2 h. (b) NaOH (4 equiv), H~2~O/MeOH 3:1 80 °C 2 h. (c) HOAc (3 M), reflux. (d) HCl, MeOH 60 °C, 2.5 h. (e) (Bpin)~2~ (1.3 equiv), KOAc (2.5 equiv), PdCl~2~(dppf) (6.5 mol %), dioxane, 90 °C. (f) BnZnBr (1.5 equiv, 0.5 M in THF), Pd(PPh~3~)~4~ (5 mol %), THF, 60 °C, 2 h. (g) Compound **4**: 3-(3-methoxy-3-oxopropyl)phenylboronic acid (commercial), Pd(Ph~3~)~4~. Compound **7**: PdCl~2~(dbpf) (5 mol %), C. Cs~2~CO~3~, DMF, 90 °C, 1.5 h. (h) *n*-Propanol/H~2~O (10:1), KOH (10 equiv), 80--100 °C. (i) **B,** PdCl~2~(dppf), Cs~2~CO~3~, DMF, 90 °C.](ml-2016-001885_0006){#sch2}

Introduction of a 3-benzoic acid moiety at the 2-position of 4-benzylbenzamide **1**, albeit nonoptimal, confirmed the potential for growth at that position (**2**, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Progressive elongation at the carboxylic acid position by introduction of methylene units (**3**--**5**) had a parabolic effect on potency, with the 3-phenylpropionic acid side chain yielding the most potent and ligand efficient derivative (**4**, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Replacement of the benzylic methylene by an ether oxygen or further elongating the hydrocarbon chain were not tolerated (cf. **5** and **6**, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}), hinting at a specific conformational requirement for the carboxylic acid-containing side chain. The cocrystal structure of sPLA~2~-IIa and **4** confirmed the previously hypothesized ligand-mediated calcium chelation, as displayed in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}.

###### sPLA~2~ Potency and Ligand Efficiencies for Compounds **2**--**6**[a](#t2fn1){ref-type="table-fn"}

![](ml-2016-001885_0007){#fx1}

Results are mean of at least two experiments. Experimental errors within 20% of value.

Calculated as plasma sPLA2 IC~50~ (μM) × compound's unbound fraction in human plasma (*F*~u~)/100. *F*~u~ = 100 -- human protein binding(%)

Ligand efficiency, LE (kcal/mol/HAC), calculated as −*RT* ln(sPLA~2~-IIa IC~50~)/heavy atom count. Ligand lipophilicity efficiency (LLE) calculated as pIC~50~ (sPLA~2~-IIa) -- logD.

Not active at maximum tested concentration (25 μM).

Not determined.

![Cocrystal structure of **4** bound to sPLA~2~-IIa. The calcium ion is depicted as a purple sphere, and relevant hydrogen bonds are displayed as dashed lines.](ml-2016-001885_0003){#fig3}

The carbonyl oxygen atom of the amide group of **4** provided the first coordination bond to calcium, analogously to **1**. The carboxylate moiety established the second coordination bond to calcium (*d* = 2.4 Å) and a hydrogen bond to the backbone amide group of G31, as shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}, while the additional phenyl ring made significant van der Waals contacts with the side chains of L2, G29, and V30. The 4-benzylbenzamide component of **4** displayed a similar interaction pattern as in **1**, except for the benzamide ring, which was rotated by ca. 50 degrees. This rotation is induced by the introduction of the substituent at the 2-position, and in the case of sPLA~2~-X, this comes with a penalty. This is exemplified by **2** and **3**, where the affinity gain is very limited, despite the addition of more lipophilic interactions ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). In type IIa, however, this conformational lock is further stabilized by an edge-to-face π interaction with F5, which is not available in sPLA2-X. This is reflected by the steep improvement in affinity when adding the substituents. For example, **3** despite having a linker too short to form the additional calcium interaction still gains more than 300-fold in affinity. This is further improved by the propanoic acid side chain of **4** where the second calcium coordination bond is properly established leading to a 2000-fold increase in potency compared to **1**. The active site of sPLA2-IIa is smaller, F5 (L5 in sPLA~2~-X) affects the benzamide moiety, and I9 (V9 in sPLA~2~-X) is located close to the hinge between the two benzyl groups of **1** (*d* = 3.7 Å), thereby slightly altering the angle in which the 4-benzyl enters the pocket and potentially introducing some strain in the fragment, where the larger pocket of sPLA~2~-X offers a less restrained binding mode

The high ligand efficiency and potency of **4**, coupled with its marked plasma sPLA~2~ inhibition ability (IC~u,50~ = 7 nM) triggered a broad characterization campaign to identify potential shortcomings.

As summarized in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, compound **4** proved to be soluble, highly permeable, and metabolically stable; characteristics that translated well *in vivo* with high bioavailability and low systemic clearance recorded in rat and dog ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). This provided a significant improvement over varespladib, which required a methyl ester prodrug approach (i.e., varespladib methyl) to afford moderate oral absorption (*F* = 40--55%) in the same species. Compound **4** did not show any significant inhibition of cytochrome P450 enzymes or ion channel activity relevant to cardiac function. Nevertheless, **4** inhibited the uptake of pivastatin in HEK293 cells transfected with the human organic anionic transporter polypeptide 1B1 (OATP1B1) at an estimated IC~50~ of 2.2 μM, as shown in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. The OATP1B1 transporter is necessary for statin's hypocholesterolemic action as it mediates their access to the liver compartment where they can then inhibit the function of HMG-CoA reductase.^[@ref23]−[@ref25]^

###### Profile[a](#t3fn1){ref-type="table-fn"} of Compound **4**

  -------------------------------------------------------------- -------- ------
  solubility (pH = 7.4) (μM)                                     98       
  P~app~ (10^--6^ cm/s)                                          40.1     
  HEP Cl~int~ (μL/min/10^--6^ cells)                             5.2      
  hERG, Na~v~1.5, IKs, K~v~4.3, Ca~v~3.2, Ca~v~1.2 IC~50~ (μM)   \>33.3   
  CYP450 IC~50~ (μM)                                             \>20     
  OATP1B1 IC~50~ (μM)                                            2.2      
  PK                                                             Rat      Dog
  dose i.v./p.o. (μmol/kg)                                       2/4      1/2
  CL (mL/min/kg)                                                 1        0.3
  *V*~ss~ (L/kg)                                                 0.22     0.26
  *F* (%)                                                        81       82
  -------------------------------------------------------------- -------- ------

Please see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.6b00188/suppl_file/ml6b00188_si_001.pdf) for experimental details.

Considering that an eventual sPLA~2~ inhibitor for the treatment of coronary artery disease will need to be coadministered with a statin, as an established standard of care, minimizing the risk for such drug--drug interaction was required. As OATP1B1 recognizes anionic compounds, we reasoned that modification of the molecular environment around the carboxylic acid of **4** might alleviate its interaction with OATP1B1. More specifically, substituting the carbon atom alpha to the carboxylic acid was of special interest as (a) it was postulated to provide a steric impediment to OTAP1B1, (b) it seemed compatible with the binding pocket of the sPLA~2~-IIa enzyme, and (c) it could enhance potency and/or selectivity through conformational "freezing" of the carboxylic acid side chain via gauche-like effects. Due to structure-based constraints and in order to minimize the impact on compound lipophilicity, we targeted small substituents and synthesized compounds **7**--**9**, following [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}.

According to [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}, the appropriate dimethyl malonate was alkylated using 3-bromobenzyl bromide. The propionic acid derivative was then obtained by hydrolysis, decarboxylation, and re-esterification to yield the methyl ester. Boronylation was accomplished by standard protocols using (Bpin)~2~ and PdCl~2~(dppf) to yield the pinacol borane ester, which could be used in the subsequent Suzuki--Miyaura coupling using the benzylated chloro benzonitrile. Finally, racemic **7**--**9** could be obtained by hydrolysis using hydroxide in alcohol/water mixtures (careful monitoring of the reaction to avoid overhydrolysis to the corresponding diacid is needed).

Addition of a methyl group (**7**, [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}) displayed an isoform-specific effect on potency: while it was neutral at sPLA~2~-IIa, it enhanced inhibition of sPLA~2~-V and reduced that of sPLA~2~-X. Overall, this yielded excellent plasma sPLA~2~ inhibition (IC~u,50~: 0.1 nM). Remarkably, structural manipulation of the carboxylic acid surroundings by an alpha-methyl group demonstrated the intended effect at a transporter level, and **7** was devoid of OATP1B1 inhibition at the maximum tested concentration (25 μM). Ethyl and cyclopropyl substitutions (**8**, **9**) were not as efficient and had a deleterious effect on metabolic stability in human hepatocytes (cf. **8**, **9**, and **7**, [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). We therefore proceeded to separate and characterize the two enantiomers of **7**. In line with expectations, sPLA~2~ inhibition was affected by stereochemistry, and the *R* enantiomer proved to be the most active, half-maximally inhibiting sPLA~2~-IIa, -V, and -X at 10, 40, and 400 nM, respectively ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). As a result, (*R*)-**7** was the most potent plasma sPLA~2~ inhibitor in this study (IC~u,50~ = 0.1 nM) and, based on its minimized risk for drug--drug interactions with statins, was progressed to further profiling.

###### sPLA~2~ Potency and Optimization Parameters for Compounds **4**--**9**

![](ml-2016-001885_0011){#gr100}

  entry     R          sPLA~2~-IIa IC~50~ (μM)[a](#t4fn1){ref-type="table-fn"}   sPLA~2~-V IC~50~ (μM)[a](#t4fn1){ref-type="table-fn"}   sPLA~2~-X IC~50~ (μM)[a](#t4fn1){ref-type="table-fn"}   plasma IC~u,50~ (nM)[b](#t4fn2){ref-type="table-fn"}   HEP Cl~int~ (μL/min/10^--6^ cells)[c](#t4fn3){ref-type="table-fn"}   OATP1B1 IC~50~ (μM)[d](#t4fn4){ref-type="table-fn"}
  --------- ---------- --------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------- -----------------------------------------------------
  4         H          0.012                                                     0.36                                                    0.28                                                    7                                                      5.2                                                                  2
  7         Me         0.011                                                     0.07                                                    0.75                                                    1                                                      9.6                                                                  NA[e](#t4fn5){ref-type="table-fn"}
  8         Et         0.021                                                     0.07                                                    0.43                                                    0.8                                                    25                                                                   ND[f](#t4fn6){ref-type="table-fn"}
  9         CyPr       0.018                                                     0.25                                                    0.58                                                    0.9                                                    21                                                                   ND[f](#t4fn6){ref-type="table-fn"}
  (*S*)-7   (*S*)-Me   0.038                                                     1.2                                                     3.8                                                     ND                                                     9.3                                                                  ND[f](#t4fn6){ref-type="table-fn"}
  (*R*)-7   (*R*)-Me   0.010                                                     0.04                                                    0.4                                                     0.1                                                    12                                                                   NA[e](#t4fn5){ref-type="table-fn"}

Mean of at least two experiments. Experimental errors within 20% of value.

Calculated as Plasma sPLA~2~ IC~50~ (μM) × unbound fraction in human plasma (*F*~u~)/100.

Intrinsic clearance of test compounds after incubation with human hepatocytes.

Inhibition of pivastatin uptake to HEK293 cells transfected with human OATP1B1.

Not active at maximum tested concentration (25 μM).

Not determined.

When incubated with HepG2 cells, (*R*)-**7** effectively inhibited sPLA~2~ activity (IC~50~ \< 14 nM) and suppressed production of sPLA~2~-IIa (IC~50~ 176 ± 28 nM) via a mechanism not yet elucidated.^[@ref7]^ Importantly, (*R*)-**7** demonstrated significant sPLA~2~ activity inhibition (IC~50~ 56 ± 10 nM) in atherosclerotic plaque homogenates, as obtained from carotid endarterectomy of coronary artery disease patients (*N* = 7).^[@ref26]^

*In vivo* PK analysis of (*R*)-**7** showed consistent high bioavailability and low clearance across different animal species, as summarized in [Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}.

###### PK Parameters of Compound (*R*)-**7**

                             mouse   rat    dog     cynomolgus
  -------------------------- ------- ------ ------- ------------
  *N* i.v./p.o.              2/2     2/2    2/2     2/2
  dose i.v./p.o. (μmol/kg)   10/50   2/8    1/3     5/15.8
  oral AUC~0-inf~ (μM × h)   69.7    70     284.1   71.3
  Cl (mL/min/kg)             9.2     1      0.2     2.8
  *V*~ss~ (L/kg)             2.8     0.21   0.15    1.1
  *F* (%)                    76.3    84     91      81

Building on the observed PK parameters and the *in vitro* sPLA~2~ inhibition measured in cynomolgus monkey plasma (IC~u,50~ 1 nM), we resolved to evaluate the *in vivo* sPLA~2~ inhibitory effect of (*R*)-**7**.

A 30 mg dose of (*R*)-**7** was orally administered to cynomolgus monkeys (*N* = 2), as shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}. This generated a concentration-dependent inhibition of sPLA~2~ activity in plasma (IC~u,80~ = 13 ± 3 nM) that well reflected the time course of (*R*)-**7**'s exposure profile ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![Vehicle-corrected plasma sPLA~2~ activity inhibition: corresponding PK--PD relationship (a) and time course (b) following oral administration of 30 mg (*R*)-**7** to cynomolgus monkeys (*N* = 2).](ml-2016-001885_0004){#fig4}

In summary, starting from the original fragment hit **1**, two design cycles based on structural information, ligand efficiency reasoning, physicochemical property control, medicinal chemistry tactics, and readily available experimental data resulted in the discovery of (*R*)-**7** (AZD2716), a novel, potent sPLA~2~ inhibitor with excellent PK properties, *in vivo* efficacy, and minimized risk for drug--drug interactions. Based on the available results and the favorable toxicological profile in rats, dogs, and cynomolgus monkeys, (*R*)-**7** was selected as a clinical candidate for the treatment of coronary artery disease.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsmedchemlett.6b00188](http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00188).Synthesis details for **2**--**9**, assay protocols, and X-ray data ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.6b00188/suppl_file/ml6b00188_si_001.pdf))
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